HUE066282T2 - Heterobiciklusos MAT2A-gátlók és eljárások rák kezelésében történõ alkalmazásukra - Google Patents
Heterobiciklusos MAT2A-gátlók és eljárások rák kezelésében történõ alkalmazásukraInfo
- Publication number
- HUE066282T2 HUE066282T2 HUE19744896A HUE19744896A HUE066282T2 HU E066282 T2 HUE066282 T2 HU E066282T2 HU E19744896 A HUE19744896 A HU E19744896A HU E19744896 A HUE19744896 A HU E19744896A HU E066282 T2 HUE066282 T2 HU E066282T2
- Authority
- HU
- Hungary
- Prior art keywords
- heterocyclic
- cancer
- treatment
- methods
- mat2a inhibitors
- Prior art date
Links
- 101000947881 Homo sapiens S-adenosylmethionine synthase isoform type-2 Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 102100035947 S-adenosylmethionine synthase isoform type-2 Human genes 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018081328 | 2018-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE066282T2 true HUE066282T2 (hu) | 2024-07-28 |
Family
ID=67439309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE19744896A HUE066282T2 (hu) | 2018-03-30 | 2019-03-28 | Heterobiciklusos MAT2A-gátlók és eljárások rák kezelésében történõ alkalmazásukra |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11524960B2 (enExample) |
| EP (1) | EP3774805B1 (enExample) |
| JP (2) | JP7350005B2 (enExample) |
| KR (1) | KR102736073B1 (enExample) |
| CN (1) | CN111936499B (enExample) |
| AR (1) | AR115326A1 (enExample) |
| AU (1) | AU2019243289B2 (enExample) |
| BR (1) | BR112020020104A2 (enExample) |
| CA (1) | CA3094476C (enExample) |
| EA (1) | EA202092320A1 (enExample) |
| ES (1) | ES2973114T3 (enExample) |
| HU (1) | HUE066282T2 (enExample) |
| IL (1) | IL277665B2 (enExample) |
| MA (1) | MA52232A (enExample) |
| MX (1) | MX2020010005A (enExample) |
| PH (1) | PH12020551507A1 (enExample) |
| PL (1) | PL3774805T3 (enExample) |
| SG (1) | SG11202009195WA (enExample) |
| TW (1) | TWI719437B (enExample) |
| UA (1) | UA127059C2 (enExample) |
| WO (1) | WO2019191470A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020123395A1 (en) | 2018-12-10 | 2020-06-18 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| LT3902803T (lt) | 2018-12-27 | 2023-04-25 | Les Laboratoires Servier | Aza-heterobicikliniai mat2a inhibitoriai ir būdai, skirti panaudoti vėžio gydymui |
| EA202191800A1 (ru) * | 2018-12-27 | 2021-09-13 | Ле Лаборатуар Сервье Сас | Азагетеробициклические ингибиторы мат2а и способы их применения для нацеливания на рак |
| SG11202112952SA (en) * | 2019-05-31 | 2021-12-30 | Servier Lab | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
| US20230227409A1 (en) * | 2020-06-10 | 2023-07-20 | Ideaya Biosciences, Inc. | Quinolinone derivatives as methionine adenosyltransferase 2a inhibitors |
| WO2021252680A1 (en) * | 2020-06-10 | 2021-12-16 | Ideaya Biosciences, Inc. | 4-arylquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| EP4165040B1 (en) * | 2020-06-10 | 2025-08-27 | Ideaya Biosciences, Inc. | 2-aminoquinazolinone derivatives as methionine adenosyltransferase 2a inhibitors |
| US20240208965A1 (en) * | 2020-06-10 | 2024-06-27 | Ideaya Biosciences, Inc. | Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| CN115960098B (zh) * | 2020-09-11 | 2026-04-10 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物的制备方法和用途 |
| CN115916778B (zh) * | 2020-09-12 | 2026-03-20 | 赛诺哈勃药业（成都）有限公司 | 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 |
| WO2022063128A1 (zh) * | 2020-09-24 | 2022-03-31 | 上海凌达生物医药有限公司 | 一类芳环或芳基杂环并吡啶酮类化合物、药物组合物及其应用 |
| CN114507231B (zh) * | 2020-11-17 | 2025-06-03 | 南京再明医药有限公司 | 内酰胺类化合物及其制备方法 |
| CN114634521A (zh) * | 2020-12-15 | 2022-06-17 | 首药控股(北京)股份有限公司 | Dna-pk选择性抑制剂及其制备方法和用途 |
| US20240124454A1 (en) * | 2020-12-31 | 2024-04-18 | Nanjing Zaiming Pharmaceutical Co., Ltd. | Tricyclic compound and use thereof |
| WO2022206730A1 (zh) * | 2021-03-29 | 2022-10-06 | 武汉人福创新药物研发中心有限公司 | 嘧啶并吡嗪酮化合物及其用途 |
| WO2022222911A1 (zh) * | 2021-04-19 | 2022-10-27 | 武汉人福创新药物研发中心有限公司 | 嘧啶酮化合物及其用途 |
| CN117412967A (zh) * | 2021-06-02 | 2024-01-16 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a抑制剂 |
| AR127404A1 (es) | 2021-10-20 | 2024-01-17 | Insilico Medicine Ip Ltd | Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos |
| CN118265700A (zh) * | 2021-11-09 | 2024-06-28 | 上海海雁医药科技有限公司 | 取代的萘啶酮衍生物、其药物组合物及应用 |
| CN114028572B (zh) * | 2021-11-30 | 2022-11-25 | 清华大学 | Mat2a抑制剂用于治疗哮喘的新应用 |
| CN118414338A (zh) * | 2021-12-21 | 2024-07-30 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a的杂环抑制剂 |
| WO2023125737A1 (en) * | 2021-12-29 | 2023-07-06 | Silexon Ai Technology Co., Ltd. | Heterocyclic compounds and use thereof |
| JP2025503186A (ja) * | 2022-01-26 | 2025-01-30 | 勤浩医▲葯▼（▲蘇▼州）有限公司 | Ｍｔａｐ欠失型がん治療用メチオニンアデノシルトランスフェラーゼ２ａ阻害剤 |
| WO2023169554A1 (zh) * | 2022-03-11 | 2023-09-14 | 赛诺哈勃药业（成都）有限公司 | 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 |
| JP2025521737A (ja) | 2022-06-27 | 2025-07-10 | 石▲薬▼集▲團▼中奇制▲薬▼技▲術▼（石家庄）有限公司 | 三環式化合物およびその使用 |
| CN117430596A (zh) * | 2022-07-13 | 2024-01-23 | 上海海和药物研究开发股份有限公司 | 二并环类mat2a抑制剂及其用途 |
| AU2023361063A1 (en) | 2022-10-13 | 2025-04-17 | Hanmi Pharm. Co., Ltd. | Novel tricyclic derivative compound and uses thereof |
| CN121241050A (zh) * | 2023-03-06 | 2025-12-30 | 甘李药业股份有限公司 | 一种甲硫氨酸腺苷转移酶2a抑制剂及其医药用途 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| AU2024302736C1 (en) * | 2023-06-14 | 2026-01-29 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | Crystal form of methionine adenosyltransferase 2a heterocyclic inhibitor, preparation method therefor, and use thereof |
| WO2025000265A1 (en) * | 2023-06-28 | 2025-01-02 | Silexon Ai Technology Co., Ltd. | Heterocyclic compounds usefull as sos1 inhibitor |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025088571A1 (en) * | 2023-10-26 | 2025-05-01 | Astrazeneca Ab | Crystalline forms of tead inhibitor |
| CN117567473B (zh) * | 2023-11-09 | 2025-07-04 | 中国药科大学 | 一种靶向同源二聚体的抑制剂及其制备方法与应用 |
| WO2025166260A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Amide substituted tricyclic guanidino compounds as prmt5 inhibitors |
| WO2025166274A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Tricyclic guanidino compounds as prmt5 inhibitors |
| WO2025166257A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Amide substituted triheterocyclic guanidino compounds as prmt5 inhibitors |
| WO2025166215A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Triheterocyclic guanidino compounds as prmt5 inhibitors |
| WO2025166229A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Tricyclic amidino compounds as prmt5 inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002517486A (ja) | 1998-06-12 | 2002-06-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｐ３８のインヒビター |
| US6576420B1 (en) | 1998-06-23 | 2003-06-10 | Regents Of The University Of California | Method for early diagnosis of, and determination of prognosis in, cancer |
| WO2004014378A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
| MX2012004846A (es) * | 2009-10-29 | 2012-10-05 | Genosco | Inhibidores de cinasa. |
| US20160115164A1 (en) * | 2014-10-22 | 2016-04-28 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) * | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| WO2018009544A1 (en) * | 2016-07-05 | 2018-01-11 | The Broad Institute, Inc. | Bicyclic urea kinase inhibitors and uses thereof |
| WO2018039972A1 (en) | 2016-08-31 | 2018-03-08 | Agios Pharmaceuticals, Inc. | Inhibitors of cellular metabolic processes |
| JP6832430B2 (ja) | 2016-08-31 | 2021-02-24 | アジオス ファーマシューティカルズ， インコーポレイテッド | 細胞代謝過程の阻害剤 |
-
2019
- 2019-03-28 US US17/040,614 patent/US11524960B2/en active Active
- 2019-03-28 UA UAA202006905A patent/UA127059C2/uk unknown
- 2019-03-28 WO PCT/US2019/024645 patent/WO2019191470A1/en not_active Ceased
- 2019-03-28 MX MX2020010005A patent/MX2020010005A/es unknown
- 2019-03-28 MA MA052232A patent/MA52232A/fr unknown
- 2019-03-28 CA CA3094476A patent/CA3094476C/en active Active
- 2019-03-28 EA EA202092320A patent/EA202092320A1/ru unknown
- 2019-03-28 JP JP2020552849A patent/JP7350005B2/ja active Active
- 2019-03-28 EP EP19744896.2A patent/EP3774805B1/en active Active
- 2019-03-28 AU AU2019243289A patent/AU2019243289B2/en active Active
- 2019-03-28 PL PL19744896.2T patent/PL3774805T3/pl unknown
- 2019-03-28 ES ES19744896T patent/ES2973114T3/es active Active
- 2019-03-28 HU HUE19744896A patent/HUE066282T2/hu unknown
- 2019-03-28 KR KR1020207030741A patent/KR102736073B1/ko active Active
- 2019-03-28 SG SG11202009195WA patent/SG11202009195WA/en unknown
- 2019-03-28 CN CN201980023557.8A patent/CN111936499B/zh active Active
- 2019-03-28 BR BR112020020104-9A patent/BR112020020104A2/pt unknown
- 2019-03-29 TW TW108111265A patent/TWI719437B/zh active
- 2019-03-29 AR ARP190100845A patent/AR115326A1/es unknown
-
2020
- 2020-09-18 PH PH12020551507A patent/PH12020551507A1/en unknown
- 2020-09-29 IL IL277665A patent/IL277665B2/en unknown
-
2023
- 2023-06-01 JP JP2023090963A patent/JP2023101762A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| TWI719437B (zh) | 2021-02-21 |
| US20210115045A1 (en) | 2021-04-22 |
| CN111936499B (zh) | 2023-09-19 |
| PL3774805T3 (pl) | 2024-05-06 |
| JP2021519783A (ja) | 2021-08-12 |
| AR115326A1 (es) | 2020-12-23 |
| CA3094476C (en) | 2025-05-06 |
| BR112020020104A2 (pt) | 2021-01-26 |
| EP3774805B1 (en) | 2024-01-10 |
| CN111936499A (zh) | 2020-11-13 |
| IL277665A (en) | 2020-11-30 |
| JP2023101762A (ja) | 2023-07-21 |
| IL277665B2 (en) | 2023-06-01 |
| TW201946629A (zh) | 2019-12-16 |
| AU2019243289A1 (en) | 2020-09-24 |
| KR102736073B1 (ko) | 2024-12-02 |
| EA202092320A1 (ru) | 2021-03-09 |
| WO2019191470A1 (en) | 2019-10-03 |
| WO2019191470A8 (en) | 2019-12-12 |
| MA52232A (fr) | 2021-02-17 |
| CA3094476A1 (en) | 2019-10-03 |
| UA127059C2 (uk) | 2023-03-29 |
| JP7350005B2 (ja) | 2023-09-25 |
| SG11202009195WA (en) | 2020-10-29 |
| EP3774805A1 (en) | 2021-02-17 |
| PH12020551507A1 (en) | 2021-09-13 |
| AU2019243289B2 (en) | 2023-01-12 |
| US11524960B2 (en) | 2022-12-13 |
| ES2973114T3 (es) | 2024-06-18 |
| NZ767697A (en) | 2025-02-28 |
| MX2020010005A (es) | 2020-10-14 |
| KR20200138769A (ko) | 2020-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE066282T2 (hu) | Heterobiciklusos MAT2A-gátlók és eljárások rák kezelésében történõ alkalmazásukra | |
| HUE061834T2 (hu) | MAT2A aza-heterobiciklusos inhibitorai és alkalmazási eljárások rák kezelésére | |
| IL284324A (en) | Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer | |
| IL272948B1 (en) | enpp1 inhibitors and their use for cancer treatment | |
| IL283149A (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| IL272470A (en) | Methods and materials for assessing and treating cancer | |
| HUE054548T2 (hu) | Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében | |
| HUE057632T2 (hu) | KRAS G12C inhibitorok és eljárások alkalmazásukra | |
| IL261721A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| IL254377B (en) | Selective akr1c3 reductase activated prodrugs and their use for treating cancer patients | |
| DK4014976T3 (da) | Aprocitentan til anvendelse i behandlingen af hypertension og relaterede sygdomme i kombination med valsartan | |
| IL255613B (en) | Heterocyclic inhibitors of erk1 and erk2 and their use in cancer therapy | |
| HUE059990T2 (hu) | 2-Oxo-tiazol-származékok A2A inhibitorként és a rákos megbetegedések kezelésében alkalmazható vegyületekként | |
| EP3487492A4 (en) | USE OF ERIBULIN AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER | |
| HUE060882T2 (hu) | Naftiridinon-származékok és alkalmazásuk arrhytmia kezelésében | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| ZA201903828B (en) | Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases | |
| IL280453B2 (en) | History of benzenesulfonamide-phenyl-alkyloxy-alkyl acids and their use in therapy. | |
| GB2583606B (en) | Indoleamine 2,3-Dioxygenase inhibitors and use of same in medicine | |
| HUE066487T2 (hu) | Regorafenib és nivolumab kombinációja rák kezelésére | |
| IL282948A (en) | Compositions and methods for treating cancer | |
| DK3937948T3 (da) | Phytoecdysoner og derivater deraf til anvendelse i behandlingen af neuromuskulære sygdomme | |
| PT3601296T (pt) | Derivados de 2-oxo-tiazóis como inibidores de a2a e compostos para uso no tratamento de cancros |